Bio-Path provides key clinical updates on BP1001-A, AML
Holdings provides an update from the Company’s ongoing Phase 1/1b clinical trial of BP1001-A in solid tumor patients and ...
Moleculin Receives Positive FDA Guidance for Acceleration of its Registration-Enabling MIRACLE Trial for R/R Acute Myeloid Leukemia (AML)
Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today ...
Bio-Path Holdings Provides Key Clinical Updates
First Solid Tumor Patient Treated with Second, Higher Dose in Phase 1/1b BP1001-A Clinical Trial Experienced Tumor Reduction and Continued Stable ...
Victoria News13h
$6.8M campaign will play critical role in Victoria cancer centre research
The BC Cancer Foundation is looking to raise $6.8 million to expand its provincial immunotherapy research program, a ...
Investornewsbreaks TC Biopharm Holdings PLC (NASDAQ: TCBP) Completes Dosing In Phase 2B AML Trial, Reports Positive Early Data
TC BioPharm (NASDAQ: TCBP) announced the completion of patient dosing in Cohort A of its ACHIEVE Phase 2B UK clinical trial, evaluating TCB008 for re ...
TC BioPharm: TCBP Announces Successful Completion of Cohort A in the ACHIEVE Clinical Trial
No adverse events related to TCB008 have occurred Evidence of stable disease following TCB008 infusion EDINBURGH, Scotland, Feb. 13, 2025 /PRNewswire/ -- TC ...
Bio-Path reports positive trial outcomes for cancer treatments
HOUSTON - Bio-Path Holdings, Inc. (NASDAQ:BPTH), a biotechnology company with a market capitalization of $3.1 million, has announced continued progress in its clinical trials for cancer treatments.
Earnings call transcript: Immunomedics Q4 2023 sees stable cash flow
Inc. (Market cap: $34.46M) has reported its financial performance for the fourth quarter of 2023, highlighting a steady cash flow and strategic advancements in its clinical pipeline. According to ...
Biotech raises Series B to test cancer drug in the clinic
Auron Therapeutics has raised a $27 million Series B financing that it will use to initiate clinical development of its lead experimental drug, AUTX-703, in blood cancers.
TCBP Announces Successful Completion of Cohort A in the ACHIEVE Clinical Trial
PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced ...